ATE277912T1 - Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer - Google Patents

Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer

Info

Publication number
ATE277912T1
ATE277912T1 AT00907524T AT00907524T ATE277912T1 AT E277912 T1 ATE277912 T1 AT E277912T1 AT 00907524 T AT00907524 T AT 00907524T AT 00907524 T AT00907524 T AT 00907524T AT E277912 T1 ATE277912 T1 AT E277912T1
Authority
AT
Austria
Prior art keywords
matrixmetalloproteinase
trione
pyrimidine
inhibitor
matrixmetalloproteinase inhibitor
Prior art date
Application number
AT00907524T
Other languages
English (en)
Inventor
Louise Helen Foley
Robert Edward Palermo
Ping Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE277912T1 publication Critical patent/ATE277912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00907524T 1999-02-12 2000-02-09 Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer ATE277912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11990399P 1999-02-12 1999-02-12
PCT/EP2000/001016 WO2000047565A1 (en) 1999-02-12 2000-02-09 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
ATE277912T1 true ATE277912T1 (de) 2004-10-15

Family

ID=22387100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907524T ATE277912T1 (de) 1999-02-12 2000-02-09 Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer

Country Status (16)

Country Link
US (1) US6265578B1 (de)
EP (1) EP1153015B1 (de)
JP (1) JP3655551B2 (de)
KR (1) KR100477160B1 (de)
CN (1) CN1147481C (de)
AR (1) AR035008A1 (de)
AT (1) ATE277912T1 (de)
AU (1) AU774487B2 (de)
BR (1) BR0008109A (de)
CA (1) CA2361605C (de)
DE (1) DE60014323T2 (de)
ES (1) ES2226790T3 (de)
PT (1) PT1153015E (de)
TR (1) TR200102334T2 (de)
WO (1) WO2000047565A1 (de)
ZA (1) ZA200106214B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002319A0 (en) * 2000-10-26 2001-12-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CZ20031083A3 (cs) * 2000-10-26 2004-03-17 Pfizer Products Inc. 5-Spiropyrimidin-2, 4, 6-trionové inhibitory metaloproteinasy
AU2002346729A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
MXPA04010550A (es) 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
JP4777067B2 (ja) * 2003-08-22 2011-09-21 ジングルス・テヒノロギース・アクチェンゲゼルシャフト ディスク状基板の結合のための方法およびこの方法を実行するための装置
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0989982B1 (de) 1997-06-21 2005-08-17 Roche Diagnostics GmbH Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
AU774487B2 (en) 2004-07-01
DE60014323D1 (de) 2004-11-04
JP2002536439A (ja) 2002-10-29
JP3655551B2 (ja) 2005-06-02
CN1339028A (zh) 2002-03-06
EP1153015B1 (de) 2004-09-29
BR0008109A (pt) 2001-11-06
US6265578B1 (en) 2001-07-24
ZA200106214B (en) 2002-10-28
PT1153015E (pt) 2004-12-31
AU2908500A (en) 2000-08-29
KR20020011963A (ko) 2002-02-09
DE60014323T2 (de) 2006-02-16
ES2226790T3 (es) 2005-04-01
WO2000047565A1 (en) 2000-08-17
TR200102334T2 (tr) 2002-01-21
EP1153015A1 (de) 2001-11-14
KR100477160B1 (ko) 2005-03-17
AR035008A1 (es) 2004-04-14
CN1147481C (zh) 2004-04-28
CA2361605C (en) 2009-01-27
CA2361605A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
EE200300195A (et) Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
IL148035A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
CY2015035I2 (el) Ενωσεις πυριμιδινης
IL154948A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
DK1175408T3 (da) Pyrimidinonforbindelser
DK1303496T3 (da) Pyrimidinderivater
NO20024127L (no) Pyrimidin-forbindelser
DK1002795T3 (da) HIV-replikationsinhiberende pyrimidiner
DE60036430D1 (de) Werkzeughalter
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
FI4231U1 (fi) Kotelo
NL1014361A1 (nl) Bevestigingsorgaan.
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
PT1171440E (pt) 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
DE50000124D1 (de) Stanzniet
ATA161299A (de) Holster
DE60014323D1 (de) Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
NO20032291D0 (no) Pyrimidinderivater
DE60027180D1 (de) Korrelator
DK1294729T3 (da) 2-aminoalkyl-thieno[2,3-d]pyrimidiner
FI20000519A7 (fi) Korrelaattori
ES1042496Y (es) "pilona sumible".
ATE286030T1 (de) 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer
FI19991956A7 (fi) Työajanseurantajärjestelmä
ES1044662Y (es) Mochila.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1153015

Country of ref document: EP

REN Ceased due to non-payment of the annual fee